NCT01634113 - Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Asthma

Interventions

DRUG

tiotropium-bromide

IMP

DRUG

tiotropium-bromide

IMP

DRUG

placebo

placebo matching tiotropium

Trial Locations (33)

Unknown

205.443.12003 Boehringer Ingelheim Investigational Site, Columbia

205.443.12005 Boehringer Ingelheim Investigational Site, Oklahoma City

205.443.12006 Boehringer Ingelheim Investigational Site, Charleston

205.443.12004 Boehringer Ingelheim Investigational Site, Summerville

205.443.01004 Boehringer Ingelheim Investigational Site, Antwerp

205.443.01002 Boehringer Ingelheim Investigational Site, Brussels

205.443.01001 Boehringer Ingelheim Investigational Site, Edegem

205.443.02002 Boehringer Ingelheim Investigational Site, Helsinki

205.443.02003 Boehringer Ingelheim Investigational Site, Turku

205.443.03003 Boehringer Ingelheim Investigational Site, Berlin

205.443.03001 Boehringer Ingelheim Investigational Site, Bochum

205.443.03002 Boehringer Ingelheim Investigational Site, Ettenheim

205.443.03010 Boehringer Ingelheim Investigational Site, Frankfurt

205.443.05001 Boehringer Ingelheim Investigational Site, Balvi

205.443.05003 Boehringer Ingelheim Investigational Site, Rēzekne

205.443.05002 Boehringer Ingelheim Investigational Site, Riga

205.443.06002 Boehringer Ingelheim Investigational Site, Vilnius

205.443.06003 Boehringer Ingelheim Investigational Site, Vilnius

205.443.10002 Boehringer Ingelheim Investigational Site, Kelantan

205.443.10001 Boehringer Ingelheim Investigational Site, Kuala Lumpur

205.443.10003 Boehringer Ingelheim Investigational Site, Kuala Pahang

205.443.04003 Boehringer Ingelheim Investigational Site, Breda

205.443.04001 Boehringer Ingelheim Investigational Site, Groningen

205.443.09001 Boehringer Ingelheim Investigational Site, Quezon City

205.443.09002 Boehringer Ingelheim Investigational Site, Quezon City

205.443.82003 Boehringer Ingelheim Investigational Site, Guri-si

205.443.82002 Boehringer Ingelheim Investigational Site, Incheon

205.443.82001 Boehringer Ingelheim Investigational Site, Seoul

205.443.07003 Boehringer Ingelheim Investigational Site, Dnipropetrovsk

205.443.07002 Boehringer Ingelheim Investigational Site, Donetsk

205.443.07005 Boehringer Ingelheim Investigational Site, Vinnytsia

205.443.07004 Boehringer Ingelheim Investigational Site, Zaporizhya

205.443.07001 Boehringer Ingelheim Investigational Site, Zaporizhzhya